keyword
https://read.qxmd.com/read/38619690/putting-more-weight-on-obesity-trials-in-heart-failure
#21
REVIEW
Josephine Harrington, Naveed Sattar, G Michael Felker, James L Januzzi, Carolyn S P Lam, Neha J Pagidipati, Ambarish Pandey, Harriette G C Van Spall, Darren K McGuire
PURPOSE OF REVIEW: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure. RECENT FINDINGS: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum...
April 15, 2024: Current Heart Failure Reports
https://read.qxmd.com/read/38617866/-using-ct-to-evaluate-cardiac-function
#22
REVIEW
Jongmin Lee
A comprehensive evaluation of cardiac function includes information in relation to cardiac output and systemic venous return. The heart is composed of four chambers: two atria and two ventricles, each with its own unique mechanical function. These four cardiac chambers, their valves, and the pulmonary circulation system are inter-related as they preload or afterload on each other. Cardiac dysfunction is a failure of global cardiac function, resulting in typical clinical manifestations. To investigate the underlying cause of cardiac dysfunction, a step-by-step evaluation of cardiac blood flow tracks is necessary...
March 2024: J Korean Soc Radiol
https://read.qxmd.com/read/38617062/trends-in-use-of-composite-endpoints-in-clinical-trials-a-comparison-between-acute-heart-failure-trials-and-covid-19-trials
#23
JOURNAL ARTICLE
Lan Shi, Christopher John Lindsell, Dandan Liu
Composite endpoints can encode multiple pieces of information and are increasingly adopted in clinical trials. Advocacy for using composite endpoints began decades ago in cardiovascular trials, leading to incorporation of patient-oriented outcomes and consideration of a hierarchical ranking system. The use of composite endpoints in coronavirus disease (COVID-19) trials has evolved similarly. We conducted a literature review to investigate the use of composite endpoints in acute heart failure and COVID-19 clinical trials...
2024: Journal of Clinical and Translational Science
https://read.qxmd.com/read/38615881/left-bundle-branch-block-induced-dilated-cardiomyopathy-definitions-pathophysiology-and-therapy
#24
REVIEW
Catarina Amaral Marques, Ana Laura Costa, Elisabete Martins
Left bundle branch block (LBBB) is a frequent finding in patients with heart failure (HF), particularly in those with dilated cardiomyopathy (DCM). LBBB has been commonly described as a consequence of DCM development. However, a total recovery of left ventricular (LV) function after cardiac resynchronization therapy (CRT), observed in patients with LBBB and DCM, has led to increasing acknowledgement of LBBB-induced dilated cardiomyopathy (LBBB-iDCM) as a specific pathological entity. Its recognition has important clinical implications, as LBBB-iDCM patients may benefit from an early CRT strategy rather than medical HF therapy only...
April 12, 2024: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://read.qxmd.com/read/38615712/mean-airway-pressure-as-a-parameter-of-lung-protective-and-heart-protective-ventilation
#25
JOURNAL ARTICLE
A Placenti, F Fratebianchi
Mean airway pressure (MAP) is the mean pressure generated in the airway during a single breath (inspiration + expiration), and is displayed on most anaesthesia and intensive care ventilators. This parameter, however, is not usually monitored during mechanical ventilation because it is poorly understood and usually only used in research. One of the main determinants of MAP is PEEP. This is because in respiratory cycles with an I:E ratio of 1:2, expiration is twice as long as inspiration. Although MAP can be used as a surrogate for mean alveolar pressure, these parameters differ considerably in some situations...
April 12, 2024: Revista española de anestesiología y reanimación
https://read.qxmd.com/read/38615668/unplanned-rehospitalisation-due-to-medication-harm-following-an-acute-myocardial-infarction
#26
JOURNAL ARTICLE
Chariclia Paradissis, Neil Cottrell, Ian D Coombes, William Y S Wang, Michael A Barras
Introduction The contribution of medication harm to rehospitalisation and adverse patient outcomes after an acute myocardial infarction (AMI) needs exploration. Rehospitalisation is costly to both patients and the healthcare facility. Following an AMI, patients are at risk of medication harm as they are often older, have multiple comorbidities and polypharmacy. This study aimed to quantify and evaluate medication harm causing unplanned rehospitalisation after an AMI. Methods This was a retrospective cohort study of patients discharged from a quaternary hospital post-AMI...
April 12, 2024: Cardiology
https://read.qxmd.com/read/38614791/updates-in-heart-failure
#27
REVIEW
Oliver L Rees, Peter Wheen, Lisa J Anderson
This review provides a contemporary overview of HF management and highlights the key studies which have informed recent European HF guidelines.
September 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/38613621/neuroimmunology-of-cardiovascular-disease
#28
REVIEW
Sara M Zarate, Annet Kirabo, Antentor O Hinton, Monica M Santisteban
PURPOSE OF REVIEW: Cardiovascular disease (CVD) is a leading cause of death and chronic disability worldwide. Yet, despite extensive intervention strategies the number of persons affected by CVD continues to rise. Thus, there is great interest in unveiling novel mechanisms that may lead to new treatments. Considering this dilemma, recent focus has turned to the neuroimmune mechanisms involved in CVD pathology leading to a deeper understanding of the brain's involvement in disease pathology...
April 13, 2024: Current Hypertension Reports
https://read.qxmd.com/read/38613598/comparative-analysis-of-treatment-options-for-chronic-heart-failure-and-depression-a-systematic-review-and-bayesian-network-meta-analysis
#29
REVIEW
Hamidreza Soleimani, Ali Nasrollahizadeh, Mohsen Hajiqasemi, Mandana Ebrahimzade, Homa Taheri, Pouya Ebrahimi, Haleh Ashraf, Marc D Samsky, Kaveh Hosseini
Different interventions have been evaluated for the treatment of depression in heart failure (HF) patients. However, clear and established recommendations are lacking. PubMed, Scopus, and Web of Science databases were systematically searched for randomized controlled trials (RCT) evaluating the effect of various treatment options on depression scores in heart failure patients. The primary outcome was a change in depression scores presented as standardized mean difference (SMD). A Bayesian network for meta-analysis was constructed...
April 13, 2024: Heart Failure Reviews
https://read.qxmd.com/read/38613319/post-diuretic-spot-urine-sodium-assessment-in-acute-heart-failure-a-retrospective-analysis
#30
JOURNAL ARTICLE
Lotte Colson, Simon Vanhentenrijk, Theodoros Kalpakos, Bram Roosens, Berlinde Von Kemp, Tim Balthazar, Stijn Lochy, Frederik H Verbrugge
AIMS: To provide real-world data on post-diuretic spot urine sodium concentration (UNa) assessment in acute heart failure (AHF) and its implications for treatment. METHODS AND RESULTS: Automated query of the electronic medical record identified patients admitted to the cardiac intensive care unit of a single tertiary care hospital between November 2018 and December 2021, who received intravenous loop diuretics. Detailed manual chart review confirmed the AHF diagnosis...
April 13, 2024: Acta Clinica Belgica
https://read.qxmd.com/read/38612843/renin-angiotensin-aldosterone-system-from-history-to-practice-of-a-secular-topic
#31
REVIEW
Sara H Ksiazek, Lilio Hu, Sebastiano Andò, Markus Pirklbauer, Marcus D Säemann, Chiara Ruotolo, Gianluigi Zaza, Gaetano La Manna, Luca De Nicola, Gert Mayer, Michele Provenzano
Renin-angiotensin-aldosterone system (RAAS) inhibitors are standard care in patients with hypertension, heart failure or chronic kidney disease (CKD). Although we have studied the RAAS for decades, there are still circumstances that remain unclear. In this review, we describe the evolution of the RAAS and pose the question of whether this survival trait is still necessary to humankind in the present age. We elucidate the benefits on cardiovascular health and kidney disease of RAAS inhibition and present promising novel medications...
April 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612710/the-role-of-stem-cells-in-the-treatment-of-cardiovascular-diseases
#32
REVIEW
Estera Bakinowska, Kajetan Kiełbowski, Dominika Boboryko, Aleksandra Wiktoria Bratborska, Joanna Olejnik-Wojciechowska, Marcin Rusiński, Andrzej Pawlik
Cardiovascular diseases (CVDs) are the leading cause of death and include several vascular and cardiac disorders, such as atherosclerosis, coronary artery disease, cardiomyopathies, and heart failure. Multiple treatment strategies exist for CVDs, but there is a need for regenerative treatment of damaged heart. Stem cells are a broad variety of cells with a great differentiation potential that have regenerative and immunomodulatory properties. Multiple studies have evaluated the efficacy of stem cells in CVDs, such as mesenchymal stem cells and induced pluripotent stem cell-derived cardiomyocytes...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612587/stem-cell-therapy-against-ischemic-heart-disease
#33
REVIEW
I-Ting Tsai, Cheuk-Kwan Sun
Ischemic heart disease, which is one of the top killers worldwide, encompasses a series of heart problems stemming from a compromised coronary blood supply to the myocardium. The severity of the disease ranges from an unstable manifestation of ischemic symptoms, such as unstable angina, to myocardial death, that is, the immediate life-threatening condition of myocardial infarction. Even though patients may survive myocardial infarction, the resulting ischemia-reperfusion injury triggers a cascade of inflammatory reactions and oxidative stress that poses a significant threat to myocardial function following successful revascularization...
March 28, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612394/the-role-of-epicardial-adipose-tissue-in-acute-coronary-syndromes-post-infarct-remodeling-and-cardiac-regeneration
#34
REVIEW
Kamil Krauz, Marcel Kempiński, Paweł Jańczak, Karol Momot, Maciej Zarębiński, Izabela Poprawa, Małgorzata Wojciechowska
Epicardial adipose tissue (EAT) is a fat deposit surrounding the heart and located under the visceral layer of the pericardium. Due to its unique features, the contribution of EAT to the pathogenesis of cardiovascular and metabolic disorders is extensively studied. Especially, EAT can be associated with the onset and development of coronary artery disease, myocardial infarction and post-infarct heart failure which all are significant problems for public health. In this article, we focus on the mechanisms of how EAT impacts acute coronary syndromes...
March 22, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38610883/how-to-manage-beta-blockade-in-older-heart-failure-patients-a-scoping-review
#35
REVIEW
Iris Parrini, Fabiana Lucà, Carmelo Massimiliano Rao, Stefano Cacciatore, Carmine Riccio, Massimo Grimaldi, Michele Massimo Gulizia, Fabrizio Oliva, Felicita Andreotti
Beta blockers (BBs) play a crucial role in enhancing the quality of life and extending the survival of patients with heart failure and reduced ejection fraction (HFrEF). Initiating the therapy at low doses and gradually titrating the dose upwards is recommended to ensure therapeutic efficacy while mitigating potential adverse effects. Vigilant monitoring for signs of drug intolerance is necessary, with dose adjustments as required. The management of older HF patients requires a case-centered approach, taking into account individual comorbidities, functional status, and frailty...
April 5, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610755/role-of-palliative-care-in-the-supportive-management-of-al-amyloidosis-a-review
#36
REVIEW
Muhammad Hamza Habib, Yun Kyoung Ryu Tiger, Danai Dima, Mathias Schlögl, Alexandra McDonald, Sandra Mazzoni, Jack Khouri, Louis Williams, Faiz Anwer, Shahzad Raza
Light chain amyloidosis is a plasma-cell disorder with a poor prognosis. It is a progressive condition, causing worsening pain, disability, and life-limiting complications involving multiple organ systems. The medical regimen can be complex, including chemotherapy or immunotherapy for the disease itself, as well as treatment for pain, gastrointestinal and cardiorespiratory symptoms, and various secondary symptoms. Patients and their families must have a realistic awareness of the illness and of the goals and limitations of treatments in making informed decisions about medical therapy, supportive management, and end-of-life planning...
March 29, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610631/arrhythmias-in-patients-with-pulmonary-hypertension-and-right-ventricular-failure-importance-of-rhythm-control-strategies
#37
REVIEW
Suneesh Anand, Edmond M Cronin
Arrhythmias frequently complicate the course of advanced pulmonary hypertension, often leading to hemodynamic compromise, functional impairment, and mortality. Given the importance of right atrial function in this physiology, the restoration and maintenance of sinus rhythm are of critical importance. In this review, we outline the pathophysiology of arrhythmias and their impact on right heart performance; describe considerations for antiarrhythmic drug selection, anesthetic and periprocedural management; and discuss the results of catheter ablation techniques in this complex and challenging patient population...
March 24, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38610175/harnessing-the-synergy-of-sglt2-inhibitors-and-continuous-ketone-monitoring-ckm-in-managing-heart-failure-among-patients-with-type-1-diabetes
#38
REVIEW
Nicola Tecce, Giorgio de Alteriis, Giulia de Alteriis, Ludovica Verde, Mario Felice Tecce, Annamaria Colao, Giovanna Muscogiuri
Heart failure (HF) management in type 1 diabetes (T1D) is particularly challenging due to its increased prevalence and the associated risks of hospitalization and mortality, driven by diabetic cardiomyopathy. Sodium-glucose cotransporter-2 inhibitors (SGLT2-is) offer a promising avenue for treating HF, specifically the preserved ejection fraction variant most common in T1D, but their utility is hampered by the risk of euglycemic diabetic ketoacidosis (DKA). This review investigates the potential of SGLT2-is in T1D HF management alongside emergent Continuous Ketone Monitoring (CKM) technology as a means to mitigate DKA risk through a comprehensive analysis of clinical trials, observational studies, and reviews...
March 29, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38610171/systematic-review-and-meta-analysis-of-the-financial-impact-of-30-day-readmissions-for-selected-medical-conditions-a-focus-on-hospital-quality-performance
#39
REVIEW
Iwimbong Kum Ghabowen, Josue Patien Epane, Jay J Shen, Xan Goodman, Zo Ramamonjiarivelo, Ferhat Devrim Zengul
BACKGROUND: The Patient Protection and Affordable Care Act (ACA) established the Hospital Quality Initiative in 2010 to enhance patient safety, reduce hospital readmissions, improve quality, and minimize healthcare costs. In response, this study aims to systematically review the literature and conduct a meta-analysis to estimate the average cost of procedure-specific 30-day risk-standardized unplanned readmissions for Acute Myocardial Infarction (AMI), Heart Failure (HF), Pneumonia, Coronary Artery Bypass Graft (CABG), and Total Hip Arthroplasty and/or Total Knee Arthroplasty (THA/TKA)...
March 29, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38609798/characteristics-and-outcomes-of-a-single-centre-cohort-of-adult-congenital-heart-disease-patients-referred-for-heart-transplant
#40
JOURNAL ARTICLE
Pavithra S Jayadeva, Stacey Peters, Su Ling Tee, Luke J Burchill, Silvana F Marasco, Leeanne Grigg, Angeline Leet, David McGiffin, Dominica Zentner
BACKGROUND: Adult congenital heart disease (ACHD) services increasingly encounter heart failure (HF) in the ageing ACHD population. Optimal timing of referral for heart transplant (HTx) evaluation in this heterogeneous population is complex and ill-defined. We aim to outline the characteristics and outcomes of ACHD patients referred for HTx from a large Australian ACHD centre. METHOD: Retrospective review of ACHD patients referred for HTx from a primary ACHD centre (1992-2021)...
April 11, 2024: Heart, Lung & Circulation
keyword
keyword
90301
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.